Table 2 Activity and efficacy data
| Â | Intent-to-treat Analysis | As-treated Analysis | ||
|---|---|---|---|---|
| Â | No | % | No | % |
Enrolled patients | 50 | 100 | 50 | 100 |
Evaluable patients | 49 | 98 | 43 | 86 |
Objective Response | 40 | 82 (CI ± 11) | 36 | 84 (CI ± 11) |
   Partial Response | 36 | 73 | 32 | 75 |
   Complete Response | 4 | 8 | 4 | 9 |
Stable Disease | 2 | 4 | 2 | 5 |
Progressive Disease | 7 | 14 | 5 | 12 |
Median Progression-free survival, months | 12 | Â | Â | Â |
   Range | 3-46+ |  |  |  |
   Progression events | 38 | 76 |  |  |
Median Overall Survival, months | 28 | Â | Â | Â |
   Range | 3-47 |  |  |  |
   Deaths | 28 | 56 |  |  |
Liver metastasectomies | 13 | Â | Â | Â |
   No/Overall patients (50) |  | 26 |  |  |
   No/Patients with liver metastases (33) |  | 39 |  |  |
   No/Patients with liver-only metastases (22) |  | 54 |  |  |